Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA)

被引：120

作者：

Hamanishi, Junzo ^{[1
]}

Takeshima, Nobuhiro ^{[2
,3
]}

Katsumata, Noriyuki ^{[4
]}

Ushijima, Kimio ^{[5
]}

Kimura, Tadashi ^{[6
]}

Takeuchi, Satoshi ^{[7
,8
]}

Matsumoto, Koji ^{[9
]}

Ito, Kimihiko ^{[10
]}

Mandai, Masaki ^{[1
,11
]}

Nakai, Hidekatsu ^{[11
]}

Sakuragi, Noriaki ^{[12
,13
]}

Watari, Hidemichi ^{[12
]}

Takahashi, Nobutaka ^{[14
]}

Kato, Hidenori ^{[15
]}

Hasegawa, Kosei ^{[16
]}

Yonemori, Kan ^{[17
]}

Mizuno, Mika ^{[18
,19
]}

Takehara, Kazuhiro ^{[20
]}

Niikura, Hitoshi ^{[21
,22
]}

Sawasaki, Takashi ^{[23
,24
]}

Nakao, Sari ^{[25
]}

Saito, Toshiaki ^{[26
]}

Enomoto, Takayuki ^{[27
]}

Nagase, Satoru ^{[28
]}

Suzuki, Nao ^{[29
]}

Matsumoto, Takashi ^{[30
]}

Kondo, Eiji ^{[31
]}

Sonoda, Kenzo ^{[32
,33
]}

Aihara, Satomi ^{[34
,35
]}

Aoki, Yoichi ^{[36
]}

Okamoto, Aikou ^{[37
]}

Takano, Hirokuni ^{[38
]}

Kobayashi, Hiroshi ^{[39
,40
]}

Kato, Hisamori ^{[41
]}

Terai, Yoshito ^{[42
,43
]}

Takazawa, Akira ^{[44
]}

Takahashi, Yusuke ^{[45
]}

Namba, Yoshinobu ^{[46
]}

Aoki, Daisuke ^{[47
]}

Fujiwara, Keiichi ^{[16
]}

Sugiyama, Toru ^{[7
,48
]}

Konishi, Ikuo ^{[49
]}

机构：

[1] Kyoto Univ, Dept Gynecol & Obstet, Grad Sch Med, Kyoto, Japan

[2] JFCR, Dept Gynecol, Canc Inst Hosp, Tokyo, Japan

[3] Int Univ Hlth & Welf Hosp, Dept Obstet & Gynecol, Otawara, Japan

[4] Musashikosugi Hosp, Dept Med Oncol, Nippon Med Sch, Kawasaki, Kanagawa, Japan

[5] Kurume Univ, Dept Obstet & Gynecol, Sch Med, Kurume, Fukuoka, Japan

[6] Osaka Univ, Dept Obstet & Gynecol, Grad Sch Med, Suita, Osaka, Japan

[7] Iwate Med Univ Hosp, Dept Obstet & Gynecol, Morioka, Iwate, Japan

[8] Kobe Tokushukai Hosp, Dept Gynecol, Kobe, Hyogo, Japan

[9] Hyogo Canc Ctr, Dept Med Oncol, Akashi, Hyogo, Japan

[10] Kansai Rosai Hosp, Dept Obstet & Gynecol, Amagasaki, Hyogo, Japan

[11] Kindai Univ, Dept Obstet & Gynecol, Fac Med, Osakasayama, Japan

[12] Hokkaido Univ, Dept Obstet & Gynecol, Grad Sch Med, Sapporo, Hokkaido, Japan

[13] Otaru Gen Hosp, Dept Gynecol, Otaru, Hokkaido, Japan

[14] Shizuoka Canc Ctr, Div Gynecol, Shizuoka, Japan

[15] Hokkaido Canc Ctr, Dept Gynecol, Sapporo, Hokkaido, Japan

[16] Saitama Med Univ, Dept Gynecol Oncol, Int Med Ctr, Hidaka, Japan

[17] Natl Canc Ctr, Dept Breast & Med Oncol, Tokyo, Japan

[18] Aichi Canc Ctr Hosp, Dept Obstet & Gynecol, Nagoya, Aichi, Japan

[19] Kagoshima Univ Hosp, Dept Obstet & Gynecol, Kagoshima, Japan

[20] Natl Hosp Org Shikoku Canc Ctr, Dept Gynecol Oncol, Matsuyama, Ehime, Japan

[21] Tohoku Univ, Dept Obstet & Gynecol, Grad Sch Med, Sendai, Miyagi, Japan

[22] Natl Hosp Org Sendai Med Ctr, Dept Obstet & Gynecol, Sendai, Miyagi, Japan

[23] Natl Hosp Org Kure Med Ctr, Dept Obstet & Gynecol, Kure, Japan

[24] SAWASAKI Obstet Gynecol Clin, Kure, Japan

[25] Univ Tsukuba Hosp, Fac Med, Dept Obstet & Gynecol, Tsukuba, Ibaraki, Japan

[26] Natl Hosp Org Kyushu Canc Ctr, Gynecol Serv, Fukuoka, Fukuoka, Japan

[27] Niigata Univ, Dept Obstet & Gynecol, Grad Sch Med & Dent Sci, Niigata, Japan

[28] Yamagata Univ Hosp, Dept Obstet & Gynecol, Yamagata, Japan

[29] St Marianna Univ, Dept Obstet & Gynecol, Sch Med, Kawasaki, Kanagawa, Japan

[30] Ehime Univ Hosp, Dept Obstet & Gynecol, Toon, Japan

[31] Mie Univ Hosp, Dept Obstet & Gynecol, Tsu, Mie, Japan

[32] Kyushu Univ Hosp, Dept Obstet & Gynecol, Fukuoka, Fukuoka, Japan

[33] Natl Hosp Org Kyushu Canc Ctr, Dept Gynecol Oncol, Fukuoka, Fukuoka, Japan

[34] Saga Univ Hosp, Fac Med, Dept Obstet & Gynecol, Saga, Japan

[35] Eguchi Hosp, Dept Med Oncol, Saga, Japan

[36] Univ Ryukyus Hosp, Dept Obstet & Gynecol, Nishihara, Okinawa, Japan

[37] Jikei Univ Hosp, Dept Obstet & Gynecol, Tokyo, Japan

[38] Jikei Univ, Dept Obstet & Gynecol, Kashiwa Hosp, Kashiwa, Chiba, Japan

[39] Nara Med Univ Hosp, Dept Obstet & Gynecol, Kashihara, Nara, Japan

[40] Ms Clin MayOne, Kashihara, Nara, Japan

[41] Kanagawa Canc Ctr, Dept Gynecol, Yokohama, Kanagawa, Japan

[42] Osaka Med Coll Hosp, Dept Gynecol Oncol, Takatsuki, Osaka, Japan

[43] Kobe Univ, Obstet & Gynecol, Grad Sch Med, Kobe, Hyogo, Japan

[44] Ono Pharmaceut Co Ltd, Data Sci, Osaka, Japan

[45] Ono Pharmaceut Co Ltd, Oncol Clin Dev Unit, Osaka, Japan

[46] Ono Pharmaceut Co Ltd, Clin Sci, Osaka, Japan

[47] Keio Univ, Dept Obstet & Gynecol, Sch Med, Tokyo, Japan

[48] St Marys Hosp, Dept Obstet & Gynecol, Kurume, Fukuoka, Japan

[49] Natl Hosp Org Kyoto Med Ctr, Kyoto, Japan

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 33期

关键词：

PHASE-III TRIAL; ANTI-PD-1; ANTIBODY; ANTITUMOR-ACTIVITY; CHEMOTHERAPY; SAFETY; AVELUMAB; CELLS;

D O I：

10.1200/JCO.21.00334

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PURPOSE This phase III, multicenter, randomized, open-label study investigated the efficacy and safety of nivolumab versus chemotherapy (gemcitabine [GEM] or pegylated liposomal doxorubicin [PLD]) in patients with platinum-resistant ovarian cancer. MATERIALS AND METHODS Eligible patients had platinum-resistant epithelial ovarian cancer, received <= 1 regimen after diagnosis of resistance, and had an Eastern Cooperative Oncology Group performance score of <= 1. Patients were randomly assigned 1:1 to nivolumab (240 mg once every 2 weeks [as one cycle]) or chemotherapy (GEM 1000 mg/m(2) for 30 minutes [once on days 1, 8, and 15] followed by a week's rest [as one cycle], or PLD 50 mg/m(2) once every 4 weeks [as one cycle]). The primary outcome was overall survival (OS). Secondary outcomes included progression-free survival (PFS), overall response rate, duration of response, and safety. RESULTS Patients (n = 316) were randomly assigned to nivolumab (n = 157) or GEM or PLD (n = 159) between October 2015 and December 2017. Median OS was 10.1 (95% CI, 8.3 to 14.1) and 12.1 (95% CI, 9.3 to 15.3) months with nivolumab and GEM or PLD, respectively (hazard ratio, 1.0; 95% CI, 0.8 to 1.3; P = .808). Median PFS was 2.0 (95% CI, 1.9 to 2.2) and 3.8 (95% CI, 3.6 to 4.2) months with nivolumab and GEM or PLD, respectively (hazard ratio, 1.5; 95% CI, 1.2 to 1.9; P = .002). There was no statistical difference in overall response rate between groups (7.6% v 13.2%; odds ratio, 0.6; 95% CI, 0.2 to 1.3; P = .191). Median duration of response was numerically longer with nivolumab than GEM or PLD (18.7 v 7.4 months). Fewer treatment-related adverse events were observed with nivolumab versus GEM or PLD (61.5% v 98.1%), with no additional or new safety risks. CONCLUSION Although well-tolerated, nivolumab did not improve OS and showed worse PFS compared with GEM or PLD in patients with platinum-resistant ovarian cancer. (C) 2021 by American Society of Clinical Oncology

引用

页码：3671 / +

页数：16

共 50 条

[21] Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
Pujade-Lauraine, Eric
Hilpert, Felix
Weber, Beatrice
Reuss, Alexander
Poveda, Andres
Kristensen, Gunnar
Sorio, Roberto
Vergote, Ignace
Witteveen, Petronella
Bamias, Aristotelis
Pereira, Deolinda
Wimberger, Pauline
Oaknin, Ana
Mirza, Mansoor Raza
Follana, Philippe
Bollag, David
Ray-Coquard, Isabelle
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (13) : 1302 - +
[22] CORAIL trial: Randomized phase III study of lurbinectedin (PM01183) versus pegylated liposomal doxorubicin (PLD) or topotecan (T) in patients with platinum-resistant ovarian cancer.
Gaillard, Stephanie
Ghamande, Sharad A.
Pardo, Beatriz
Lorusso, Domenica
Vergote, Ignace
Papai, Zsuzsanna
O'Malley, D.
Kristeleit, Rebecca Sophie
Redondo, Andres
Timcheva, Constanta
Fernandez, Cristian
Nieto, Antonio
Soto-Matos, Arturo
Moss, Keren Rachel
Baumann, Klaus H.
Ray-Coquard, Isabelle
Oaknin, Ana
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[23] PRECEDENT: A Randomized Phase II Trial Comparing Vintafolide (EC145) and Pegylated Liposomal Doxorubicin (PLD) in Combination Versus PLD Alone in Patients With Platinum-Resistant Ovarian Cancer
Naumann, R. Wendel
Coleman, Robert L.
Burger, Robert A.
Sausville, Edward A.
Kutarska, Elzbieta
Ghamande, Sharad A.
Gabrail, Nashat Y.
DePasquale, Stephen E.
Nowara, Elzbieta
Gilbert, Lucy
Gersh, Robert H.
Teneriello, Michael G.
Harb, Wael A.
Konstantinopoulos, Panagiotis A.
Penson, Richard T.
Symanowski, James T.
Lovejoy, Chandra D.
Leaman, Christopher P.
Morgenstern, David E.
Messmann, Richard A.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (35) : 4400 - +
[24] A randomized, phase II/III study of pegylated-liposomal-doxorubicin and atezolizumab (IND #134427) versus pegylated-liposomal-doxorubicin, bevacizumab and atezolizumab versus pegylated-liposomal-doxorubicin and bevacizumab in platinum-resistant ovarian cancer (NRG-GY009)
O'Cearbhaill, Roisin
Sill, Michael
Duong, Hoa
Waggoner, Steven
Grisham, Rachel
Backes, Floor
Mannel, Robert
Tanyi, Janos
Powell, Matthew
Mathews, Cara
Ghamande, Sharad
Mcnally, Leah
Olawaiye, Alexander
Bender, David
Duska, Linda
Lankes, Heather
Zamarin, Dmitriy
Schilder, Russell
Bookman, Michael
Aghajanian, Carol
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (SUPPL_4) : A4 - A4
[25] Pegylated liposomal doxorubicin and carboplatin versus paclitaxel and carboplatin as first-line treatment for Chinese patients with ovarian cancer: A multi-center, randomized, open-label trial
Shen, Yuanming
Kong, Beihua
Xia, Bairong
Wang, Fei
Yin, Rutie
Li, Qingshui
Yue, Ying
Kang, Shan
He, Liping
Wang, Ke
Meng, Yuanguang
Wang, Shixuan
Qu, Pengpeng
Huang, Xianghua
Guo, Ruixia
Yan, Ping
Pan, Mei
Lou, Ge
Cheng, Wenjun
Xie, Xing
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[26] Adverse Event Profile by Folate Receptor Status for Vintafolide and Pegylated Liposomal Doxorubicin in Combination, Versus Pegylated Liposomal Doxorubicin Alone, in Platinum-Resistant Ovarian Cancer Exploratory Analysis of the Phase II PRECEDENT Trial
Herzog, Thomas J.
Kutarska, Elzbieta
Bidzinsk, Mariusz
Symanowski, Jim
Binh Nguyen
Rangwala, Reshma A.
Naumann, R. Wendel
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 (09) : 1580 - 1585
[27] PemBOv trial: Pembrolizumab plus bevacizumab with or without pegylated liposomal doxorubicin-based chemotherapy in patients with platinum-resistant ovarian cancer.
Michels, Judith
Ghiringhelli, Francois
Frenel, Jean-Sebastien
Brard, Caroline
Genestie, Catherine
Balleyguier, Corinne
Ciccolini, Joseph
Paci, Angelo
You, Benoit
Floquet, Anne
Eberst, Lauriane
Bahleda, Rastilav
Pautier, Patricia
Colomba, Emeline
Pommeret, Fanny
Massard, Christophe
Marabelle, Aurelien
Leary, Alexandra
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[28] Pegylated liposomal doxorubicin in partially platinum-sensitive, platinum-resistant, or platinum-refractory ovarian cancer: a prospective study
Zhang, Ying
Yuan, Zhen
Zhang, Guo-Nan
Li, Qing-Shui
Cui, Man-Hua
Cheng, Wen-Jun
Meng, Yuan-Guang
Wu, Xiao-Hua
Yue, Ying
Wang, Li
Hou, Jian-Qing
Li, Chang-Zhong
Qu, Peng-Peng
Sun, Li-Xin
Tao, Guang-Shi
Li, Gui-Ling
Chen, Ya-Qing
Ren, Fang
Cao, Dong-Yan
Shen, Keng
ONCOLOGIST, 2024,
[29] Randomized phase II study of the PDGFR antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer
McGuire, William P.
Penson, Richard T.
Gore, Martin
Herraez, Antonio Casado
Peterson, Patrick
Shahir, Ashwin
Ilaria, Robert, Jr.
BMC CANCER, 2018, 18
[30] Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer
William P. McGuire
Richard T. Penson
Martin Gore
Antonio Casado Herraez
Patrick Peterson
Ashwin Shahir
Robert Ilaria
BMC Cancer, 18

← 1 2 3 4 5 →